Mecasermin rinfabate - Shire

Drug Profile

Mecasermin rinfabate - Shire

Alternative Names: HGT-ROP-001; Insulin-like growth factor-I/insulin-like growth factor binding protein-3; IPLEX; Mecasermin rinfabate; Premiplex; rhIGF-I/rhIGFBP-3; SHP607; SomatoKine

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Insmed
  • Developer Insmed; Shire
  • Class Antihyperglycaemics; Growth factors
  • Mechanism of Action Insulin like growth factor binding protein 3 stimulants; Insulin-like growth factor I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Insulin resistance; Growth disorders; Retinopathy of prematurity; Muscular dystrophies
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Retinopathy of prematurity
  • Market Withdrawal Growth disorders
  • Suspended Muscular dystrophies
  • No development reported Amyotrophic lateral sclerosis; Lung disorders
  • Discontinued Burns; Fracture; Insulin resistance; Lipodystrophy; Postmenopausal osteoporosis; Short stature; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Lung-disorders(In neonates, Prevention) in USA
  • 12 Sep 2017 Mecasermin rinfabate receives Fast Track designation for Lung disorders (In neonates, Prevention) in USA
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top